HENGRUI PHARMA(01276)

48.000-0.440-0.91%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- BlackRock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Decreases to 5.76% on Oct 6 from 6.34% - HKEX
  THOMSON REUTERS · 10-09 17:26
  BlackRock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Decreases to 5.76% on Oct 6 from 6.34% - HKEX
- HENGRUI PHARMA: Citigroup Inc. Acquires Shares, Long Position Rises to 5.24%
  HK Disclosure · 10-09 17:24
  HENGRUI PHARMA: Citigroup Inc. Acquires Shares, Long Position Rises to 5.24%
- HENGRUI PHARMA: BlackRock, Inc. Disposes of Shares, Long Position Falls to 5.76%
  HK Disclosure · 10-09 17:18
  HENGRUI PHARMA: BlackRock, Inc. Disposes of Shares, Long Position Falls to 5.76%
- Hengrui Pharma's Prostate Cancer Drug Gets European Approval
  MT Newswires Live · 10-09 11:42
  Hengrui Pharma's Prostate Cancer Drug Gets European Approval
- Movement Alert｜HENGRUI PHARMA Falls 3.43% in Regular Trading, Hong Kong Innovative Drug Sector Under Broad Pressure
  Market Focus · 10-09 09:40
  Movement Alert｜HENGRUI PHARMA Falls 3.43% in Regular Trading, Hong Kong Innovative Drug Sector Under Broad Pressure
- HENGRUI PHARMA: JPMorgan Chase & Co. Disposes of Shares, Long Position Falls to 9.87%
  HK Disclosure · 10-08 17:15
  HENGRUI PHARMA: JPMorgan Chase & Co. Disposes of Shares, Long Position Falls to 9.87%
- HENGRUI PHARMA Has Repurchased 585,000 A Shares as of the End of September
  Stock News · 10-08 17:14
  HENGRUI PHARMA Has Repurchased 585,000 A Shares as of the End of September
- HENGRUI PHARMA: The Capital Group Companies, Inc. Disposes of Shares, Long Position Falls to 10.96%
  HK Disclosure · 10-08 17:13
  HENGRUI PHARMA: The Capital Group Companies, Inc. Disposes of Shares, Long Position Falls to 10.96%
- Movement Alert｜HENGRUI PHARMA Intraday Rise 3.68%, Buyback and Immunology Pipeline Optimism Drive Gains
  Market Focus · 10-08 09:55
  Movement Alert｜HENGRUI PHARMA Intraday Rise 3.68%, Buyback and Immunology Pipeline Optimism Drive Gains
- HENGRUI PHARMA: BlackRock, Inc. Disposes of Shares, Long Position Falls to 5.96%
  HK Disclosure · 10-06
  HENGRUI PHARMA: BlackRock, Inc. Disposes of Shares, Long Position Falls to 5.96%
- BlackRock's Long Position in H-Shares of Jiangsu Hengrui Increases to 6.99% on Sept 30 from 5.96% - HKEX
  THOMSON REUTERS · 10-05
  BlackRock's Long Position in H-Shares of Jiangsu Hengrui Increases to 6.99% on Sept 30 from 5.96% - HKEX
- UBS Group Ag's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Decreases to 4.59% on Sept 25 from 5.17% - HKEX
  THOMSON REUTERS · 10-02
  UBS Group Ag's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Decreases to 4.59% on Sept 25 from 5.17% - HKEX
- Major Drugmakers Turn to China for Licensing Deals
  Reuters · 10-02
  Major Drugmakers Turn to China for Licensing Deals
- HENGRUI PHARMA: BlackRock, Inc. Disposes of Shares, Long Position Falls to 5.96%
  HK Disclosure · 10-02
  HENGRUI PHARMA: BlackRock, Inc. Disposes of Shares, Long Position Falls to 5.96%
- HENGRUI PHARMA: UBS Group AG Disposes of Shares, Long Position Falls to 4.59%
  HK Disclosure · 10-02
  HENGRUI PHARMA: UBS Group AG Disposes of Shares, Long Position Falls to 4.59%
- Movement Alert｜HENGRUI PHARMA Falls 3.27% in Regular Trading, Profit-Taking After Novo Nordisk Deal Rally Amid Broad Pharma Sector Weakness
  Market Focus · 10-02
  Movement Alert｜HENGRUI PHARMA Falls 3.27% in Regular Trading, Profit-Taking After Novo Nordisk Deal Rally Amid Broad Pharma Sector Weakness
- Hong Kong Stocks Close Higher as Property Stimulus Fails to Enthuse; Pharma Emerges as Safe Haven
  Stock News · 09-30
  Hong Kong Stocks Close Higher as Property Stimulus Fails to Enthuse; Pharma Emerges as Safe Haven
- Daiwa: Hengrui Pharma (01276) Reaches Licensing Deal with Novo Nordisk for HRS-1596; Total Transaction Value and Upfront Payment Both Attractive
  Stock News · 09-30
  Daiwa: Hengrui Pharma (01276) Reaches Licensing Deal with Novo Nordisk for HRS-1596; Total Transaction Value and Upfront Payment Both Attractive
- Morgan Stanley Maintains Overweight Rating on Hengrui Pharma (01276) with HK$82 Target Price
  Stock News · 09-30
  Morgan Stanley Maintains Overweight Rating on Hengrui Pharma (01276) with HK$82 Target Price
- AI Drug Discovery Sector Heats Up: ChinaAMC Hang Seng Biotech (03069) Rises Over 4% Intraday, ChinaAMC Innovative Drugs (03525) Gains Over 3% in Afternoon Session
  Stock News · 09-30
  AI Drug Discovery Sector Heats Up: ChinaAMC Hang Seng Biotech (03069) Rises Over 4% Intraday, ChinaAMC Innovative Drugs (03525) Gains Over 3% in Afternoon Session
Company Profile
Company Name
HENGRUI PHARMA
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.hrs.com.cn
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The Company focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The Company's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The Company mainly conducts its businesses in domestic and foreign markets.
- 08-19
  Interim Report
  2026 INTERIM REPORT
  2026 INTERIM REPORT
- 08-19
  Interim Report
  INTERIM RESULTS ANNOUNCEMENT FORTHE SIX MONTHS ENDED JUNE 30, 2026
  INTERIM RESULTS ANNOUNCEMENT FORTHE SIX MONTHS ENDED JUNE 30, 2026
- 03-26
  Annual Report
  2025 ANNUAL REPORT
  2025 ANNUAL REPORT

1D
5D
Day
Week
Month

Loading ...

High

49.100

Open

48.980

Volume%

1.86

Low

46.480

48.440

T/O Rate

2.75%

To The Moon

HENGRUI PHARMA(01276)

Company Profile

Most Discussed